HeartFlow's FFRCT technology in coronary CTA reduces 5-year mortality by 60%+ in PAD patients undergoing major vascular surgery compared to standard care.

HeartFlow reveals new study in Journal of Vascular Surgery showing coronary CTA with FFRCT care reduces mortality by 60%+ at five years in PAD patients undergoing major vascular surgery, exceeding current standard care. This significant reduction in mortality rate may be attributed to HeartFlow's FFRCT technology, a non-invasive method for diagnosing hemodynamically significant coronary lesions in patients with suspected CAD.

May 08, 2024
3 Articles